Elevation Oncology Inc
NASDAQ:ELEV
Intrinsic Value
The intrinsic value of one
ELEV
stock under the Base Case scenario is
1.047
USD.
Compared to the current market price of 0.365 USD,
Elevation Oncology Inc
is
Undervalued by 65%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Elevation Oncology Inc.
Fundamental Analysis
Revenue & Expenses Breakdown
Elevation Oncology Inc
Balance Sheet Decomposition
Elevation Oncology Inc
| Current Assets | 82.2m |
| Cash & Short-Term Investments | 80.7m |
| Other Current Assets | 1.5m |
| Non-Current Assets | 29k |
| PP&E | 29k |
Free Cash Flow Analysis
Elevation Oncology Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Elevation Oncology Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-45.7m
USD
|
|
Operating Income
|
-45.7m
USD
|
|
Other Expenses
|
-2.3m
USD
|
|
Net Income
|
-48m
USD
|
ELEV Profitability Score
Profitability Due Diligence
Elevation Oncology Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Elevation Oncology Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ELEV Solvency Score
Solvency Due Diligence
Elevation Oncology Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Elevation Oncology Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ELEV Price Targets Summary
Elevation Oncology Inc
Dividends
Current shareholder yield for
ELEV is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ELEV
stock under the Base Case scenario is
1.047
USD.
Compared to the current market price of 0.365 USD,
Elevation Oncology Inc
is
Undervalued by 65%.